Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 3/20 | 0.73 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.73 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.73 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.73 |
| ▸ | PTGIR | P43119 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.73 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
| ▸ | PGR | P06401 | 1/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL674246 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL10742477 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL11079261 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL29424279 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL29420457 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL23352779 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL11379818 | 0.91 | PTGER4 (0.70) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| Trimoprostil SCHEMBL11024670 | 0.91 | PTGER3 (0.64) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| Trimoprostil SCHEMBL564049 | 0.91 | PTGER3 (0.64) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| Trimoprostil SCHEMBL11226793 | 0.91 | PTGER3 (0.64) | PTGFRPTGER3PTGER4PTGER2PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250215396-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12281329-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240263135-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11932870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. | 2024-03-19 | — | — | US | disclosed |
| US-20230126434-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | EDITAS MEDICINE, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20220401487-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11413309-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-11390884-B2 | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells | EDITAS MEDICINE, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| EP-2349242-B1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS INC (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180282762-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | EDITAS MEDICINE, INC. | 2018-10-04 | — | — | US | disclosed |
| EP-3294896-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | Editas Medicine, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016182959-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | EDITAS MEDICINE, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-8722739-B2 | Amino acid salts of prostaglandins | NOVAER HOLDINGS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140031423-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8623918-B2 | Amino acid salts of prostaglandins | NOVAER HOLDINGS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8470882-B2 | — | — | 2013-06-25 | — | — | US | disclosed |
| US-20100105771-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105775-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126434-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | ZFX, DCLRE1B, APOBEC3C | PTGFR 4534/4885PTGER3 4817/4885PTGER4 4838/4885 |
| US-20100105771-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | PTGIS, PTGES, PTGIR | PTGFR 7/4885PTGER3 16/4885PTGER4 17/4885 |
| US-20100105775-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | PTGIS, PTGES, PTGIR | PTGFR 7/4885PTGER3 16/4885PTGER4 17/4885 |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | PTGFR 4090/4885PTGER3 1098/4885PTGER4 3714/4885 |
| US-20180282762-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | ZFX, DCLRE1B, APOBEC3C | PTGFR 4534/4885PTGER3 4817/4885PTGER4 4838/4885 |
| US-11390884-B2 | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells | ZFX, DCLRE1B, APOBEC3C | PTGFR 4534/4885PTGER3 4817/4885PTGER4 4838/4885 |
| US-20140031423-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | PTGIS, PTGES, PTGIR | PTGFR 7/4885PTGER3 16/4885PTGER4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.